Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG–PCL nanomicelles

2012 ◽  
Vol 81 (3) ◽  
pp. 470-477 ◽  
Author(s):  
Takanori Kanazawa ◽  
Ken Sugawara ◽  
Ko Tanaka ◽  
Shogo Horiuchi ◽  
Yuuki Takashima ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cell Penetrating Peptide ◽  
Systemic Delivery ◽  
Anti Vegf ◽  
Cell Penetrating

Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression

2012 ◽  
Vol 434 (1-2) ◽  
pp. 488-493 ◽  
Author(s):  
Yeon Lim Jang ◽  
Ui Jeong Yun ◽  
Min Sang Lee ◽  
Myung Goo Kim ◽  
Sohee Son ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Growth Suppression ◽  
Cell Penetrating Peptide ◽  
Cell Penetrating ◽  
Tumor Growth Suppression

The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine

Biomaterials ◽  
2010 ◽  
Vol 31 (6) ◽  
pp. 1429-1443 ◽  
Author(s):  
Young-Suk Choi ◽  
Jue Yeon Lee ◽  
Jin Sook Suh ◽  
Young-Min Kwon ◽  
Seung-Jin Lee ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Cell Penetrating Peptide ◽  
Low Molecular Weight ◽  
Systemic Delivery ◽  
Cell Penetrating ◽  
A Cell

Rapid delivery of paclitaxel with an organic solvent-free system based on a novel cell penetrating peptide for suppression of tumor growth

2017 ◽  
Vol 5 (37) ◽  
pp. 7768-7774
Author(s):  
Yuping Wei ◽  
Liang Zhang ◽  
Yankai Fu ◽  
Xia Xu
Keyword(s):  
Tumor Growth ◽  
Organic Solvent ◽  
Delivery System ◽  
Hela Cells ◽  
Cell Penetrating Peptide ◽  
Free System ◽  
Tail Vein ◽  
Tail Vein Injection ◽  
Cell Penetrating ◽  
Solvent Free System

PTX is rapidly translocated into HeLa cells with the help of R7. The intracellular PTX concentration of R7/PTX complex group is 3 fold that of the free PTX group. This delivery system does not contain any organic solvent. The tumor growth is significantly suppressed by a tail vein injection of the R7/PTX complex.

A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt

Angiogenesis ◽  
2011 ◽  
Vol 14 (3) ◽  
pp. 355-369 ◽  
Author(s):  
Rajeshwari R. Mehta ◽  
Tohru Yamada ◽  
Brad N. Taylor ◽  
Konstantin Christov ◽  
Marissa L. King ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cell Penetrating Peptide ◽  
Cell Penetrating ◽  
A Cell

scholarly journals Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs

Pharmaceutics ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 365
Author(s):  
Dina V. Hingorani ◽  
Maria F. Camargo ◽  
Maryam A. Quraishi ◽  
Stephen R. Adams ◽  
Sunil J. Advani
Keyword(s):  
Immune System ◽  
Cancer Therapy ◽  
Tumor Tissue ◽  
Tissue Concentration ◽  
Cell Penetrating Peptides ◽  
Cell Penetrating Peptide ◽  
Peptide Drug ◽  
Systemic Delivery ◽  
Drug Conjugate ◽  
Cell Penetrating

Recent advances in immunotherapy have revolutionized cancer therapy. Immunotherapies can engage the adaptive and innate arms of the immune system. Therapeutics targeting immune checkpoint inhibitors (i.e., CTLA-4; PD-1, and PD-L1) have shown efficacy for subsets of cancer patients by unleashing an adaptive antitumor immune response. Alternatively, small molecule immune modulators of the innate immune system such as toll-like receptor (TLR) agonists are being developed for cancer therapy. TLRs function as pattern recognition receptors to microbial products and are also involved in carcinogenesis. Reisquimod is a TLR 7/8 agonist that has antitumor efficacy. However, systemic delivery free resiquimod has proven to be challenging due to toxicity of nonspecific TLR 7/8 activation. Therefore, we developed a targeted peptide-drug conjugate strategy for systemic delivery of resiquimod. We designed an activatable cell penetrating peptide to deliver resiquimod specifically to the tumor tissue while avoiding normal tissues. The activatable cell penetrating peptide (ACPP) scaffold undergoes enzymatic cleavage by matrix metalloproteinases 2/9 in the extracellular matrix followed by intracellular lysosomal cathepsin B mediated release of the free resiquimod. Importantly, when conjugated to ACPP; the tumor tissue concentration of resiquimod was more than 1000-fold greater than that of surrounding non-cancerous tissue. Moreover, systemic ACPP-resiquimod delivery produced comparable therapeutic efficacy to localized free resiquimod in syngeneic murine tumors. These results highlight a precision peptide-drug conjugate delivery.

Sign in / Sign up

Export Citation Format

Share Document